MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cited by
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Molecular mechanisms for tumour resistance to chemotherapy
Pan, S., Li, Z., He, Z., Qiu, J., & Zhou, S. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12581 · Cited by 401
The ERK and JNK pathways in the regulation of metabolic reprogramming
Papa, S., Choy, P. M., & Bubici, C. (2019) · Oncogene · doi:10.1038/s41388-018-0582-8 · Cited by 381
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
“Reactivation can occur through alterations or mutations to upstream molecules such as RTKs, RAS, RAF, or NF1, reinforcing the signaling pathway [141,156].”
BackgroundSHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation
Couto, J. A., Huang, A. Y., Konczyk, D. J., Goss, J. A., Fishman, S. J., Mulliken, J. B., Warman, M. L., & Greene, A. K. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.01.018 · Cited by 298
“MEK1 inhibitors currently are in use against various cancers.(18) Further study is required to determine whether these drugs have efficacy for AVM.”
BackgroundMethodACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway
Zhang, Q., Lu, S., Li, T., Yu, L., Zhang, Y., Zeng, H., Qian, X., Bi, J., & Lin, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1156-5 · Cited by 297
Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sánchez, P., Nguyen, C. B., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312268 · Cited by 291
Hafner, M., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.05.005 · Cited by 250
“Like CDK4/6 inhibition, MEK inhibition is anti-mitogenic in breast cancer cells, causing cells to arrest at the G1/S transition (Caunt et al., 2015; Meloche and Pouysségur, 2007).”
BackgroundLearning single-cell perturbation responses using neural optimal transport
Bunne, C., Stark, S. G., Gut, G., del Castillo, J. S., Levesque, M., Lehmann, K.-V., Pelkmans, L., Krause, A., & Rätsch, G. (2023) · Nature Methods · doi:10.1038/s41592-023-01969-x · Cited by 202
Sun, C., Fang, Y., Yin, J., Chen, J., Ju, Z., Zhang, D., Chen, X., Vellano, C. P., Jeong, K. J., Ng, P. K.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5148 · Cited by 231
Asl, E. R., Amini, M., Najafi, S., Mansoori, B., Mokhtarzadeh, A., Mohammadi, A., Lotfinejad, P., Bagheri, M., Shirjang, S., Lotfi, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119499 · Cited by 231
Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer
Maik-Rachline, G., Hacohen-Lev-Ran, A., & Seger, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051194 · Cited by 224
“More problematic is the fact that even in those sensitive cancers, a resistance to the drugs is developed after a relatively short period of successful treatment [19,34,35].”
BackgroundResistance to TRK inhibition mediated by convergent MAPK pathway activation
Cocco, E., Schram, A. M., Kulick, A., Misale, S., Won, H. H., Yaeger, R., Razavi, P., Ptashkin, R., Hechtman, J. F., Toska, E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0542-z · Cited by 217
Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis
Liu, S., Ma, H., Zhang, H., Deng, C., & Xin, P. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108793 · Cited by 208
Su, J., Wu, G., Ye, Y., Zhang, J., Zeng, L., Huang, X., Zheng, Y., Bai, R., Zhuang, L., Li, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01978-0 · Cited by 196
“) pathways [24, 25], and many transcripts in these pathways were hypermethylated in our results (Fig.”
ResultTargeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
PDK1: At the crossroad of cancer signaling pathways
Gagliardi, P. A., Puliafito, A., & Primo, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.014 · Cited by 196
Oshima, K., Khiabanian, H., da Silva-Almeida, A. C., Tzoneva, G., Abate, F., Ambesi-Impiombato, A., Sanchez-Martin, M., Carpenter, Z., Penson, A., Perez-Garcia, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608420113 · Cited by 194
“Moreover, suppression of MAPK signaling with the U0126 and the PD0325901 MEK inhibitors (33) showed increased antileukemic activity in Kras G12D mutant cells and enhanced the cytotoxic activity of methotrexate (Fig.”
BackgroundRegulatory cells and the effect of cancer immunotherapy
Iglesias-Escudero, M., Arias-González, N., & Martínez-Cáceres, E. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01714-0 · Cited by 191
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications
Wei, Q., Qian, Y., Yu, J., & Wong, C. C. (2020) · Oncogene · doi:10.1038/s41388-020-01432-7 · Cited by 191
Inhibitory feedback control of NF-κB signalling in health and disease
Prescott, J. A., Mitchell, J. P., & Cook, S. J. (2021) · Biochemical Journal · doi:10.1042/bcj20210139 · Cited by 187
Self-citationThe path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Targeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 184
“Both melanoma and CFC mutations occur in two regions of the MEK protein—in the N-terminal negative regulatory region or in the ATP-binding region of the N-terminal lobe [122].”
BackgroundMEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. K. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 184
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
Lu, N., & Malemud, C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153792 · Cited by 175
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 172
Self-citationControl of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · The FEBS Journal · doi:10.1111/febs.14122 · Cited by 170
Self-citationERK signalling as a regulator of cell motility
Tanimura, S., & Takeda, K. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx048 · Cited by 166
“Consistent with the divergent roles of ERK signalling in cell regulation, constitutive activation of ERK signalling results in tumour formation and progression (4 6), and thus inhibition of ERK signalling is widely thought to be a promising strategy for cancer therapy (7, 8).”
BackgroundKitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
“It has been demonstrated that activation of MAPK signaling induces transcription of negative feedback genes including SPRYs and DUSPs (9,42).”
BackgroundInfluentialERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Self-citationBrady, D. C., Crowe, M. S., Greenberg, D. N., & Counter, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1190 · Cited by 173
“MEKi are also being tested in a broad spectrum of other cancers (13,14).”
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
Salaroglio, I. C., Mungo, E., Gazzano, E., Kopecka, J., & Riganti, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102505 · Cited by 169
Dual-specificity MAP kinase phosphatases in health and disease
Seternes, O.-M., Kidger, A. M., & Keyse, S. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.09.002 · Cited by 141
Olea-Flores, M., Zuñiga-Eulogio, M. D., Mendoza-Catalán, M. A., Rodríguez-Ruiz, H. A., Castañeda-Saucedo, E., Ortuño-Pineda, C., Padilla-Benavides, T., & Navarro-Tito, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122885 · Cited by 146
“Interestingly, mutations in MEK1/2 have been found in patients with melanoma, lung, and colorectal cancer [27,151].”
BackgroundAllele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
Gao, Y., Chang, M. T., McKay, D., Na, N., Zhou, B., Yaeger, R., Torres, N. M., Muniz, K., Drosten, M., Barbacid, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1452 · Cited by 143
“These inhibitors bind to an allosteric site adjacent to the ATP pocket (16-19).”
BackgroundFigueiredo, C. R., Kalirai, H., Sacco, J. J., Azevedo, R., Duckworth, A. D., Slupsky, J. R., Coulson, J. M., & Coupland, S. E. (2020) · The Journal of Pathology · doi:10.1002/path.5384 · Cited by 167
Targeting growth hormone function: strategies and therapeutic applications
Lu, M., Flanagan, J. U., Langley, R. J., Hay, M. P., & Perry, J. K. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0036-y · Cited by 143
The expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 149
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“Downstream negative feedback results from upregulation of the MAPK phosphatases DUSP1/4/6 and ERK-mediated inhibitory phosphorylation of CRAF, MEK1/2 and kinase suppressor of RAS 1 (KSR1), among other mechanisms 23,26 .”
MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation
Jin, L., Chun, J., Pan, C., Li, D., Lin, R., Alesi, G. N., Wang, X., Kang, H.-B., Song, L., Wang, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.012 · Cited by 132
“Previous reports showed that cRaf binding sites in MEK1 consist of Ser221/217, whereas predicted cisplatin binding sites in MEK1 are Met56 and Cys104 (Caunt et al., 2015; Yamamoto et al., 2015).”
BackgroundVascular Anomalies: From a Clinicohistologic to a Genetic Framework
Greene, A. K., & Goss, J. A. (2018) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000004294 · Cited by 130
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
BackgroundATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicinska, E., Sulahian, R., Goodale, A., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 128
“Preclinical and clinical studies have shown that a major mode of intrinsic and acquired resistance to MEK or BRAF inhibitor monotherapy in RAS- or BRAF-mutant cancers is the reactivation of the RTK-RAS-MAPK pathway by mechanisms (Caunt et al., 2015; Lito et al., 2013), such as loss of feedback inhibition (Corcoran et…”
BackgroundMetastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 142
Kerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124
Biernacka, A., Tsongalis, P. D., Peterson, J. D., de Abreu, F. B., Black, C. C., Gutmann, E. J., Liu, X., Tafe, L. J., Amos, C. I., & Tsongalis, G. J. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.03.001 · Cited by 120
“Targeting KRAS downstream effector MEK1/2 has emerged as the most promising approach for advancedstage KRAS mutant lung cancer (11,22).”
BackgroundRoskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Jerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M. P., Boer, J. M., Besselink, N. J. M., Boeree, A., van de Ven, C., de Groot‐Kruseman, H. A., de Haas, V., et al. (2017) · Leukemia · doi:10.1038/leu.2017.303 · Cited by 128
CD 47‐signal regulatory protein α signaling system and its application to cancer immunotherapy
Murata, Y., Saito, Y., Kotani, T., & Matozaki, T. (2018) · Cancer Science · doi:10.1111/cas.13663 · Cited by 111
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
Casey, D., Demko, S., Sinha, A. K., Mishra-Kalyani, P. S., Shen, Y. L., Khasar, S. G., Goheer, M. A., Helms, W. S., Pan, L., Xu, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5032 · Cited by 111
“downstream Ras signaling through the ubiquitously expressed Ras– Raf–MEK–ERK signaling cascade (13).”
BackgroundYarchoan, M., Cope, L., Ruggieri, A. N., Anders, R. A., Noonan, A. M., Goff, L. W., Goyal, L., Lacy, J., Li, D., Patel, A. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152670 · Cited by 110
Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential
Boudreau, M. W., Peh, J., & Hergenrother, P. J. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00338 · Cited by 116
Unexpected therapeutic effects of cisplatin
Raudenská, M., Balvan, J., Fojtů, M., Gumulec, J., & Masařík, M. (2019) · Metallomics · doi:10.1039/c9mt00049f · Cited by 114
de Jong, P. R., Taniguchi, K., Harris, A. R., Bertin, S., Takahashi, N., Duong, J., Campos, A. D., Powis, G., Corr, M., Karin, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11551 · Cited by 113
MAPK/ERK Signaling in Regulation of Renal Differentiation
Kurtzeborn, K., Kwon, H. N., & Kuure, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071779 · Cited by 116
“Further highlighting the importance of the MAPK/ERK pathway in tissue homeostasis, mutations in RAS, B-RAF, RAF1, MEK1, or MEK2 appear to drive uncontrolled cell proliferation and survival of cancer cells in a growth factor-independent manner [37,38].”
Falcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 108
“Of the remaining ten mice, eight displayed stable and only two progressive disease (P = 0.078 T/N + anti-PD-L1 versus T/N; Fig.”
BackgroundInfluentialKidger, A. M., Rushworth, L. K., Stellzig, J., Davidson, J., Bryant, C., Bayley, C., Caddye, E., Rogers, T., Keyse, S. M., & Caunt, C. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614684114 · Cited by 108
“Int J Biochem Cell Biol 41(12):2351–2355.”
BackgroundResultSelf-citationDu, J., Lan, T., Liao, H., Feng, X., Chen, X., Liao, W., Hou, G., Xu, L., Feng, Q., Xie, K., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01482-9 · Cited by 107
“Generally, ERK kinase can only be activated by the upstream kinase MEK, whose role was more likely to be a “kinase gatekeeper” for ERK [31].”
BackgroundAllosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation
Pino, G. L. G., Li, K., Park, E., Schmoker, A. M., Ha, B. H., & Eck, M. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107207118 · Cited by 107
Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer
Shang, J., Zha, H., & Sun, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582657 · Cited by 101
Pan, X., Pei, J., Wang, A., Wen, S., Feng, L., Bu, F., Zhu, Y., Zhang, L., Wang, G., & Ouyang, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.022 · Cited by 97
Nagathihalli, N. S., Castellanos, J. A., Lamichhane, P., Messaggio, F., Shi, C., Dai, X., Rai, P., Chen, X., VanSaun, M. N., & Merchant, N. B. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0634 · Cited by 90
“The clinical success of MEK inhibitors in Kras mutant melanoma and lung cancer implicate their therapeutic potential in PDAC (9,10).”
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 93
“…for the emerging rug resistance, and it was found that the resistance may in fact e mediated by multifactorial mechanisms (Poulikakos and Rosen, 011; Lito et al., 2013; Sale and Cook, 2014; Caunt et al., 2015). any of the mechanisms are similar to those described for the ntrinsic resistance.”
BackgroundSomatic activating mutations in MAP2K1 cause melorheostosis
Kang, H., Jha, S., Deng, Z., Fratzl‐Zelman, N., Cabral, W. A., Ivovic, A., Meylan, F., Hanson, E. P., Lange, E., Katz, J. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03720-z · Cited by 90
The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation
Grasso, M. J., Bond, G. J., Kim, Y., Boyd, S. D., Dzebo, M. M., Dzebo, M. M., Valenzuela, S., Schibrowsky, N. A., Alwan, K. B., Blackburn, N. J., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101314 · Cited by 87
“Although targeting the protein kinase catalytic activity of MEK1/2 is approved in the setting of BRAF metastatic melanoma (22, 38) and is under investigation in several other cancers, resistance mechanisms limited clinical durability.”
BackgroundRam, T., Singh, A. K., Kumar, A., Singh, H., Pathak, P., Grishina, M., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., Verma, A., et al. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00145h · Cited by 88
Cellular and molecular effects of yeast probiotics on cancer
Saber, A., Alipour, B., Faghfoori, Z., & Yari Khosroushahi, A. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2016.1179622 · Cited by 83
“Many human cancers contain activating mutations in genes encoding RTKs, RAS, BRAF, CRAF, MEK1, or MEK2, which act as driving oncogenes; consequently, many cancers demonstrate deregulated activation of an enhanced dependency on ERK1/2 signaling (Caunt et al., 2015).”
BackgroundMAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 96
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90
Jones, G. G., del Río, I. B., Sari, S., Sekerim, A., Young, L. C., Hartig, N., Areso Zubiaur, I., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 80
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 80
Self-citationTargeting the MAPK Pathway in RAS Mutant Cancers
Hymowitz, S. G., & Malek, S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031492 · Cited by 77
Yang, L., Shen, C., Estrada‐Bernal, A., Robb, R. N., Chatterjee, M., Sebastian, N., Webb, A., Mo, X. M., Chen, W., Krishnan, S., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab871 · Cited by 82
“Thus, focus has been largely on downstream KRAS targets to develop a treatment that abolishes mutant KRAS activity (7,8).”
BackgroundBhayadia, R., Krowiorz, K., Haetscher, N., Jammal, R., Emmrich, S., Obulkasim, A., Fiedler, J., Schwarzer, A., ROUHI, A. M., Heuser, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2204 · Cited by 85
Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.066 · Cited by 72
“, cobimetinib and binimetinib) or are in development (Caunt et al., 2015).”
BackgroundFlores, K., Yadav, S. S., Katz, A. A., & Seger, R. (2018) · Neuroendocrinology · doi:10.1159/000494085 · Cited by 80
Poon, E., Mullins, S., Watkins, A., Williams, G. S., Koopmann, J.-O., Di Genova, G., Cumberbatch, M., Veldman-Jones, M., Grosskurth, S. E., Sah, V., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0268-8 · Cited by 75
“Therefore, small molecule inhibitors of MEK have been used in a range of cancer indications and have shown activity [5].”
BackgroundSelf-citationMEK inhibitors under development for treatment of non-small-cell lung cancer
Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 74
“The MEK proteins are downstream effectors of RAF, encoded by seven different genes (MEK1, MEK2, and MKK3-7) [28].”
BackgroundShee, K., Yang, W., Hinds, J. W., Hampsch, R. A., Varn, F. S., Traphagen, N. A., Patel, K., Cheng, C., Jenkins, N. P., Kettenbach, A. N., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171818 · Cited by 73
“MEK–ERK pathway activation can affect many downstream targets implicated in the cell cycle and survival (Caunt et al., 2015).”
BackgroundProtein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway
García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72
Kong, P., Dong, J., Li, W., Li, Z., Gao, R., Liu, X., Wang, J., Su, Q., Wen, B., Ouyang, W., et al. (2023) · Advanced Science · doi:10.1002/advs.202301244 · Cited by 86
Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines
Kegel, B. D., Quinn, N., Thompson, N., Adams, D. J., & Ryan, C. J. (2021) · Cell Systems · doi:10.1016/j.cels.2021.08.006 · Cited by 71
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
“MEK inhibitors have been widely tested in multiple cancer types, including lung cancer (14, 15), and trametinib and cobimetinib have both been approved to treat BRAFmutant melanoma (16, 17).”
BackgroundTRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non–Small Cell Lung Carcinogenesis
Wang, Q., Gao, G., Zhang, T., Yao, K., Chen, H., Park, M. H., Yamamoto, H., Wang, K., Ma, W., Malakhova, M. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0429 · Cited by 77
“Additionally, MEK1 and MEK2 are the only known substrates of BRAF compared with other RAFs, making BRAF a preferential candidate for investigating the effects of MAPK signal transduction in tumorigenesis (11,12).”
Azumi, J., Tsubota, T., Sakabe, T., & Shiota, G. (2016) · Cancer Science · doi:10.1111/cas.13006 · Cited by 74
Chen, L.-L., Wang, Y.-B., Song, J.-X., Deng, W.-K., Lu, J.-H., Ma, L.-L., Yang, C.-B., Li, M., & Xue, Y. (2017) · Autophagy · doi:10.1080/15548627.2017.1371393 · Cited by 67
Rukhlenko, O. S., Khorsand, F., Krstić, A., Rožanc, J., Alexopoulos, L. G., Rauch, N., Erickson, K. E., Hlavacek, W. S., Posner, R. G., Gómez‐Coca, S., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.002 · Cited by 72
“In our model, the phosphorylation and dephosphorylation of S218 and S222 on MEK, and the T202/185 and Y204/187 on ERK1/2 is based on a model of a dual (de)phosphorylation cycle developed earlier (Markevich et al., 2004a).”
BackgroundInfluentialDiscovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Wei, J., Hu, J., Wang, L., Xie, L., Jin, M. S., Chen, X., Liu, J., & Jin, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01528 · Cited by 66
Chen, C., Hsia, T., Yeh, M., Chen, T., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 64
“Consequently, many cancers bearing these MAPK-related mutant genes exhibit a survival addiction to ERK1/2 signaling (Caunt et al., 2015; Kidger and Keyse, 2016).”
BackgroundComputational targeting of allosteric site of MEK1 by quinoline‐based molecules
Singh, R., Bhardwaj, V. K., & Purohit, R. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3709 · Cited by 63
“Phosphorylation of ERKs occurs at the conserved tyrosine and threonine residues of the T‐E‐Y motif inside their activation loop.(3)”
BackgroundInfluentialHeightman, T. D., Berdini, V., Braithwaite, H. E., Buck, I. M., Cassidy, M. A., Castro, J., Courtin, A., Day, J. E. H., East, C., Fazal, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00421 · Cited by 63
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
Satoh, T. K., Mellett, M., Meier-Schiesser, B., Fenini, G., Otsuka, A., Beer, H., Rordorf, T., Maul, J., Hafner, J., Navarini, A. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128678 · Cited by 66
“Small-molecule inhibitors of the mitogen-activated protein kinase (MAPK) signaling pathways including extracellular signal–regulated kinase (ERK) and MAPK/ ERK kinase 1 and 2 (MEK1 and -2) have also shown their efficacy in the treatment of various cancers, especially melanoma (3, 4).”
Background
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.